Skip to main content
SpringerLink
Log in

Alemtuzumab/anakinra/ruxolitinib

Lymphoma relapse and lack of drug effect: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Trantham T, et al. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale. Journal of Oncology Pharmacy Practice 26: 1005-1008, No. 4, 2020. Available from: URL: http://doi.org/10.1177/1078155219878774

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab/anakinra/ruxolitinib. Reactions Weekly 1823, 29 (2020). https://doi.org/10.1007/s40278-020-83657-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-83657-8

Search

Navigation